Compare AbbVie Inc (ABBV) vs BlackBerry Limited (BB) Price & Performance

AbbVie (ABBV) trades at $249.19, up 1.28% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust immunology drug performance from Skyrizi and Rinvoq are offsetting Humira patent losses, driving revenue growth to $61.16B in 2025. The stock is near its pivot point of $247, with support at $245 and resistance at $249.

The outlook remains positive with a consensus price target of $281.33, though high P/E of 70.05 and looming patent cliffs in the 2030s present risks. Dividend growth and institutional accumulation support the buy case, but margin compression and debt levels warrant monitoring.

BlackBerry (BB) trades at $8.98, up 2.28% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats and a positive 2026 net income forecast of $60M signal a turnaround, though 2025 saw a net loss of $79M. The stock's valuation remains elevated with a P/E of 89.8 and P/S of 9.22. News highlights growth in QNX and secure communications, with the stock gaining 125% year-to-date as of August 2026, though it has pulled back 35% from its peak.

The outlook hinges on execution of growth in QNX and secure communications, with FY2027 guidance suggesting 11% revenue growth and 20% adjusted EBITDA margin expansion. Risks include premium valuation, cyclical industry exposure, and reliance on long-dated QNX royalties. Analyst consensus is cautious with 85.7% hold ratings, but a $10.50 price target implies potential upside if operational improvements materialize.